ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2010
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Guideline
- Adalimumab in Focus: Evaluating Effectiveness and Safety in Non-Infectious Uveitis at a Tertiary Referral Center in Türkiye.Turkish journal of ophthalmology · 2025Observational
- Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells.Journal of neuroinflammation · 2018Article
- Tolerance Induction in Relation to the Eye.Frontiers in immunology · 2018Review
- Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation.Frontiers in pharmacology · 2018Article
- Anti-inflammatory effect of Heliotropium indicum Linn on lipopolysaccharide-induced uveitis in New Zealand white rabbits.International journal of ophthalmology · 2016Article
- Novel Therapies in Development for Diabetic Macular Edema.Current diabetes reports · 2015Review
- Red eyes presenting with a fistulous lesion in the left lower extremity: a case report.Journal of medical case reports · 2015Article
- Understanding autoimmunity in the eye: from animal models to novel therapies.Discovery medicine · 2014Article
- Article
- Green tea extract treatment alleviates ocular inflammation in a rat model of endotoxin-induced uveitis.PloS one · 2014Article
- Immunopathogenesis of ocular Behçet's disease.Journal of immunology research · 2014Review
- Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis.Drug design, development and therapy · 2014Review
- Surveying uveitis specialists-a call for consensus.Journal of ophthalmic inflammation and infection · 2012Article
- Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Recent patents on biomedical engineering · 2012Article
- Mucosal inflammation in spondylarthritides: past, present, and future.Current rheumatology reports · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndogenous uveitis is a sight-threatening disease. In addition to corticosteroids, immunosuppressive agents are commonly used to treat patients with severe course. Immunosuppressive drugs act nonspecifically, rather than providing a specific interaction with the critical pathogenetic pathways of uveitis. Better knowledge of the basic mechanisms underlying uveitis and of the molecules that are important for regulating inflammation has helped to create new and more specific treatment approaches. Biological therapy for inflammatory diseases employs substances that interfere with specific molecules or pathways induced in the body during the inflammatory process.
methodsThis review gives an overview on molecules that play a critical role in the pathogenetic process of uveitis, as has been observed in patients or the respective animal models, and summarizes the current experience with biologicals for the treatment of uveitis refractive to conventional immunosuppressives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.